ASTH
Price
$28.90Alerts
Change
+$0.22 (+0.77%)
Updated
Nov 20 closing price
Capitalization
1.74B
96 days until earnings call
Intraday BUY SELL Signals
DVA
Price
$161.03Alerts
Change
+$4.69 (+3.00%)
Updated
Nov 20 closing price
Capitalization
12.21B
82 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ASTH vs DVA

ASTH vs DVA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ASTH vs. DVA commentary
Nov 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASTH is a Hold and DVA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ASTH with price predictions
Nov 20, 2026

ASTH in -10.35% downward trend, sliding for three consecutive days on November 19, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ASTH declined for three days, in 232 of 300 cases, the price declined further within the following month. The odds of a continued downward trend are 77%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ASTH as a result. In 62 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.

The Moving Average Convergence Divergence Histogram (MACD) for ASTH turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 29 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.

ASTH moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ASTH crossed bearishly below the 50-day moving average on November 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 57%.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +3.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where ASTH advanced for three days, in 240 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

ASTH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 136 of 195 cases where ASTH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. ASTH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.099) is normal, around the industry mean (204.532). P/E Ratio (42.878) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.153) among similar stocks. P/S Ratio (0.485) is also within normal values, averaging (2.688).

The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ASTH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

A.I.Advisor
a Summary for DVA with price predictions
Nov 20, 2026

DVA sees MACD Histogram crosses below signal line

DVA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 10, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 40 instances where the indicator turned negative. In 26 of the 40 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 65%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DVA as a result. In 51 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 59%.

DVA moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for DVA crossed bearishly below the 50-day moving average on November 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.

The 50-day moving average for DVA moved below the 200-day moving average on November 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.

The Aroon Indicator for DVA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DVA's RSI Oscillator exited the oversold zone, 18 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +6.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where DVA advanced for three days, in 245 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.

DVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 7 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. DVA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-15.956) is normal, around the industry mean (204.532). P/E Ratio (15.431) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.436) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.153) among similar stocks. P/S Ratio (0.968) is also within normal values, averaging (2.688).

The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.

FUNDAMENTALS RATINGS
ASTH vs DVA: Fundamental Ratings
ASTH
DVA
OUTLOOK RATING
1..100
5368
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
60
Fair valued
PROFIT vs RISK RATING
1..100
10060
SMR RATING
1..100
837
PRICE GROWTH RATING
1..100
6459
P/E GROWTH RATING
1..100
7716
SEASONALITY SCORE
1..100
34n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DVA's Valuation (60) in the Medical Or Nursing Services industry is in the same range as ASTH (80) in the null industry. This means that DVA’s stock grew similarly to ASTH’s over the last 12 months.

DVA's Profit vs Risk Rating (60) in the Medical Or Nursing Services industry is somewhat better than the same rating for ASTH (100) in the null industry. This means that DVA’s stock grew somewhat faster than ASTH’s over the last 12 months.

DVA's SMR Rating (7) in the Medical Or Nursing Services industry is significantly better than the same rating for ASTH (83) in the null industry. This means that DVA’s stock grew significantly faster than ASTH’s over the last 12 months.

DVA's Price Growth Rating (59) in the Medical Or Nursing Services industry is in the same range as ASTH (64) in the null industry. This means that DVA’s stock grew similarly to ASTH’s over the last 12 months.

DVA's P/E Growth Rating (16) in the Medical Or Nursing Services industry is somewhat better than the same rating for ASTH (77) in the null industry. This means that DVA’s stock grew somewhat faster than ASTH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ASTHDVA
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
68%
Momentum
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
59%
MACD
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 2 days ago
65%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
58%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
58%
Advances
ODDS (%)
Bullish Trend 6 days ago
76%
Bullish Trend 17 days ago
69%
Declines
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 3 days ago
53%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
71%
Aroon
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
54%
COMPARISON
Comparison
Nov 22, 2026
Stock price -- (ASTH: $28.90 vs. DVA: $161.03)
Brand notoriety: ASTH: Not notable vs. DVA: Notable
Both companies represent the Hospital/Nursing Management industry
Current volume relative to the 65-day Moving Average: ASTH: 101% vs. DVA: 90%
Market capitalization -- ASTH: $1.74B vs. DVA: $12.21B
ASTH [@Hospital/Nursing Management] is valued at $1.74B. DVA’s [@Hospital/Nursing Management] market capitalization is $12.21B. The market cap for tickers in the [@Hospital/Nursing Management] industry ranges from $20.9K to $107.17B. The average market capitalization across the [@Hospital/Nursing Management] industry is $5.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASTH’s FA Score shows that 0 FA rating(s) are green while DVA’s FA Score has 2 green FA rating(s).

  • ASTH’s FA Score: 0 green, 5 red.
  • DVA’s FA Score: 2 green, 3 red.
According to our system of comparison, DVA is a better buy in the long-term than ASTH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ASTH’s TA Score shows that 5 TA indicator(s) are bullish while DVA’s TA Score has 4 bullish TA indicator(s).

  • ASTH’s TA Score: 5 bullish, 5 bearish.
  • DVA’s TA Score: 4 bullish, 7 bearish.
According to our system of comparison, ASTH is a better buy in the short-term than DVA.

Price Growth

ASTH (@Hospital/Nursing Management) experienced а -9.12% price change this week, while DVA (@Hospital/Nursing Management) price change was -7.75% for the same time period.

The average weekly price growth across all stocks in the @Hospital/Nursing Management industry was -11.67%. For the same industry, the average monthly price growth was -11.86%, and the average quarterly price growth was +0.44%.

Reported Earning Dates

ASTH is expected to report earnings on Feb 25, 2027.

DVA is expected to report earnings on Feb 11, 2027.

Industries' Descriptions

@Hospital/Nursing Management (-11.67% weekly)

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ASTH and

Correlation & Price change

A.I.dvisor tells us that ASTH and PNTG have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ASTH and PNTG's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASTH
1D Price
Change %
ASTH100%
+0.77%
PNTG - ASTH
32%
Poorly correlated
+1.61%
HCA - ASTH
30%
Poorly correlated
+3.31%
HCSG - ASTH
29%
Poorly correlated
-0.20%
STLN - ASTH
28%
Poorly correlated
-5.66%
ADUS - ASTH
26%
Poorly correlated
+1.18%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BND71.330.42
+0.59%
Vanguard Total Bond Market ETF (BND)
UUPP25.16-0.01
-0.04%
Principal CLO ETF (UUPP)
TFLR50.24-0.09
-0.18%
T. Rowe Price Floating Rate ETF (TFLR)
FNK61.01-0.86
-1.39%
First Trust Mid Cap Value AlphaDEX Fund (FNK)
DVYA46.89-0.80
-1.68%
iShares Asia/Pacific Dividend ETF (DVYA)